Clinical Trial Update: First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on first-line nab-paclitaxel, cisplatin, and carilizumab in metastatic triple-negative breast cancer (mTNBC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Carilizumab (Carilizumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN